

# Viread® For Hepatitis B Registration In The Developing World

## Approved

1. Argentina	May 2011
2. Armenia	September 2011
3. Aruba	September 2011
4. Azerbaijan	May 2011
5. Bangladesh	June 2011
6. Benin	April 2015
7. Bhutan	November 2017
8. Bolivia	September 2011
9. Brazil	December 2010
10. Burkina Faso	September 2014
11. Cameroon	January 2016
12. Central African Republic	January 2015
13. Chad	November 2016
14. Chile	November 2011
15. Colombia	March 2013
16. Congo, Republic of the	November 2016
17. Costa Rica	March 2013
18. Curacao	October 2011
19. Dominican Republic	April 2016
20. Egypt	March 2012

21. El Salvador	December 2015
22. Ethiopia	August 2015
23. Gabon	November 2014
24. Georgia	June 2011
25. Guatemala	June 2011
26. Guinea	February 2014
27. Guyana	July 2017
28. Honduras	July 2012
29. Ivory Coast	November 2016
30. Kazakhstan	May 2012
31. Kenya	September 2014
32. Kyrgyzstan	July 2012
33. Madagascar	October 2017
34. Mali	November 2014
35. Mauritania	November 2016
36. Mexico	November 2012
37. Moldova	January 2013
38. Mongolia	September 2014
39. Namibia	August 2015
40. Nepal	September 2017

41. Niger	March 2014
42. Nigeria	July 2018
43. Pakistan	January 2013
44. Panama	February 2012
45. Paraguay	September 2011
46. Peru	June 2011
47. Philippines	March 2014
48. Senegal	November 2016
49. Sint Maarten	June 2016
50. South Africa	February 2017
51. Tanzania	August 2015
52. Thailand	May 2013
53. Togo	November 2016
54. Trinidad and Tobago	February 2018
55. Turkmenistan	April 2014
56. Uganda	February 2017
57. Ukraine	September 2012
58. Uruguay	April 2011
59. Uzbekistan	May 2011
60. Zambia	November 2015
61. Zimbabwe	July 2015

## Filed

1. Jamaica	January 2011
2. Malawi	April 2014
3. Venezuela	April 2016

### **Terms and Definitions**

**Approved:** Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

**Filed:** Dossier submitted and review pending.

### **Note**

There can be no guarantee that marketing approval for Viread® for the treatment of hepatitis B will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.